&nbsp;

Sep 2018

Drug

filgrastim

Other Name(s): Neupogen®, Grastofil®, Nivestym®, Nypozi®, Filra™

Quick Link(s):

Sep 2025

Drug

flutamide

Other Name(s): Euflex®

Quick Link(s):

Aug 2025

Drug

fulvestrant

Other Name(s): Faslodex®

Quick Link(s):

Aug 2025

Regimen

FLVS

Cancer Type:

Breast

Intent: Palliative

Funding:

ODB - General Benefit

fulvestrant

Drugs Used:

fulvestrant

Quick Link(s):

Regimen Monograph

Aug 2025

Regimen

FLTM

Cancer Type:

Genitourinary,

Prostate

Intent: Palliative

Funding:

ODB - General Benefit

flutamide

Drugs Used:

flutamide

Quick Link(s):

Regimen Monograph

Oct 2016

Regimen

NLTM

Cancer Type:

Genitourinary,

Prostate

Intent: Palliative

Funding:

ODB - General Benefit

niLUTAmide

Drugs Used:

niLUTAmide

Quick Link(s):

Regimen Monograph

Sep 2018

Regimen

FC(PO)+R

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

ODB - General Benefit

cyclophosphamide - oral tablets

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma

Drugs Used:

riTUXimab,

fludarabine (Unfunded),

cyclophosphamide,

riTUXimab (subcut)

Quick Link(s):

Regimen Monograph

Aug 2020

Regimen

FC(PO)+R

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Previously Untreated Chronic Lymphocytic Leukemia

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Second Line - Chronic Lymphocytic Leukemia

ODB Limited Use

fludarabine - For the first-line treatment of CLL in combination with rituximab (tablets; with or without cyclophosphamide)

ODB Limited Use

fludarabine - For second-line therapy of patients with CLL who have failed or are intolerant to chlorambucil (tablets)

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Previously Untreated Chronic Lymphocytic Leukemia

Drugs Used:

Quick Link(s):

Regimen Monograph

Aug 2020

Regimen

FC(PO)

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

ODB Limited Use

fludarabine - For second-line therapy of patients with CLL who have failed or are intolerant to chlorambucil (tablets)

ODB - General Benefit

cyclophosphamide - oral tablets

Drugs Used:

fludarabine,

cyclophosphamide

Quick Link(s):

Regimen Monograph

Jun 2019

Regimen

FC(PO)

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

ODB - General Benefit

cyclophosphamide - oral tablets

Drugs Used:

fludarabine (Unfunded),

cyclophosphamide

Quick Link(s):

Regimen Monograph

Jun 2019

Regimen

FCM(PO)

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

ODB - General Benefit

cyclophosphamide - oral tablets

Drugs Used:

fludarabine (Unfunded),

cyclophosphamide,

mitoXANTRONE